ginkgo (Ginkgo biloba)

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• ADHD [Insufficient Evidence]
• age-related macular degeneration [Insufficient Evidence]
• aging [Insufficient Evidence]
• allergic rhinitis [Insufficient Evidence]
• altitude sickness prevention [Insufficient Evidence]
• angina [Insufficient Evidence]
• anxiety [Possibly Effective]
• asthma [Insufficient Evidence]
• autism spectrum disorder [Insufficient Evidence]
• bronchitis [Insufficient Evidence]
• cancer prevention, ovarian [Insufficient Evidence]
• cardiovascular dz prevention [Possibly Ineffective]
• chronic fatigue syndrome [Insufficient Evidence]
• CKD [Insufficient Evidence]
• cocaine dependence [Insufficient Evidence]
• cognitive decline, age-related [Possibly Ineffective]
• cognitive function [Insufficient Evidence]
• cognitive impairment [Insufficient Evidence]
• cognitive impairment, chemo-related [Possibly Ineffective]
• colorectal CA [Insufficient Evidence]
• COPD [Insufficient Evidence]
• cough [Insufficient Evidence]
• dementia [Possibly Effective]
• depression [Insufficient Evidence]
• diabetes mellitus, type 2 [Insufficient Evidence]
• diabetic retinopathy [Insufficient Evidence]
• dry eye dz [Insufficient Evidence]
• dyslexia [Insufficient Evidence]
• fibromyalgia [Insufficient Evidence]
• gastric CA [Insufficient Evidence]
• glaucoma [Insufficient Evidence]
• hearing loss [Possibly Effective]
• hemorrhoids [Insufficient Evidence]
• HTN [Possibly Ineffective]
• HTN, pulmonary [Insufficient Evidence]
• hypercholesterolemia [Insufficient Evidence]
• intestinal parasite infection [Insufficient Evidence]
• Lyme dz [Insufficient Evidence]
• migraine prophylaxis [Insufficient Evidence]
• multiple sclerosis [Possibly Ineffective]
• pancreatic CA [Insufficient Evidence]
• Parkinson dz [Insufficient Evidence]
• peripheral arterial dz [Insufficient Evidence]
• premenstrual syndrome [Possibly Effective]
• quality of life [Insufficient Evidence]
• radiation dermatitis [Insufficient Evidence]
• radiation exposure [Insufficient Evidence]
• Raynaud phenomenon [Insufficient Evidence]
• scabies [Insufficient Evidence]
• schizophrenia [Possibly Effective]
• seasonal affective disorder [Insufficient Evidence]
• sexual dysfxn [Insufficient Evidence]
• sexual dysfxn, antidepressant-induced [Possibly Ineffective]
• stroke [Possibly Effective]
• tardive dyskinesia [Possibly Effective]
• tinnitus [Possibly Ineffective]
• vascular dementia [Possibly Effective]
• venous thromboembolism [Insufficient Evidence]
• vertigo [Possibly Effective]
• vitiligo [Insufficient Evidence]
• wound healing [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

ADHD, peds pts

[Insufficient Evidence]

Dose: 50 mg PO bid; Info: for pts 3-17 yo; used w/ American ginseng extract

age-related macular degeneration

[Insufficient Evidence]

Dose: 60-240 mg/day PO divided bid-tid

allergic rhinitis

[Insufficient Evidence]

Dose: 2 gtt 0.05% in eye(s) tid

altitude sickness prevention

[Insufficient Evidence]

Dose: 80-120 mg PO bid

angina

[Insufficient Evidence]

Dose: 315 mg PO tid; Info: used w/ standard tx

anxiety

[Possibly Effective]

Dose: 80-160 mg PO tid

chronic fatigue syndrome

[Insufficient Evidence]

Dose: 120-180 mg PO qd

cognitive function

[Insufficient Evidence]

Dose: 240-600 mg PO x1; Alt: 80-300 mg/day PO divided qd-tid

cognitive impairment

[Insufficient Evidence]

Dose: 40 mg PO tid; Alt: 200 mg PO qd starting 48h before electroconvulsive tx, then cont. until electroconvulsive tx end

colorectal CA

[Insufficient Evidence]

Dose: 350 mg IV qd on days 1-6 of 21-day cycle; Info: used w/ 5-FU

dementia

[Possibly Effective]

Dose: 120-240 mg/day PO divided qd-tid; Alt: 150 mg PO tid

diabetes mellitus, type 2

[Insufficient Evidence]

Dose: 120 mg PO qd

diabetic retinopathy

[Insufficient Evidence]

Dose: 120 mg PO qd

dry eye dz

[Insufficient Evidence]

Dose: 1 gtt 0.05% in eye(s) tid

dyslexia, peds pts

[Insufficient Evidence]

Dose: 80 mg PO qd; Info: for pts 5-16 yo

fibromyalgia

[Insufficient Evidence]

Dose: 200 mg PO qd; Info: used w/ coenzyme Q10

gastric CA

[Insufficient Evidence]

Dose: 250 mg PO bid

glaucoma

[Insufficient Evidence]

Dose: 120-160 mg/day PO divided bid-tid

hearing loss

[Possibly Effective]

Dose: 40-175 mg IV qd; Alt: 120 mg PO bid

migraine prophylaxis, adult pts

[Insufficient Evidence]

Dose: 60 mg PO bid

migraine prophylaxis, peds pts

[Insufficient Evidence]

Dose: 80 mg PO bid

pancreatic CA

[Insufficient Evidence]

Dose: 350 mg IV qd on days 1-6 of 21-day cycle; Info: used w/ 5-FU

Parkinson dz

[Insufficient Evidence]

Dose: 80 mg PO tid

peripheral arterial dz

[Insufficient Evidence]

Dose: 120-240 mg/day PO divided qd-bid

premenstrual syndrome

[Possibly Effective]

Dose: 40 mg PO tid; Alt: 80 mg PO bid: Info: start on day 16, cont. until day 5 of next cycle

quality of life

[Insufficient Evidence]

Dose: 120 mg PO qd

radiation dermatitis

[Insufficient Evidence]

Dose: apply cream topically bid-tid; Start: 15 days before XRT

radiation exposure

[Insufficient Evidence]

Dose: 120 mg PO qd

Raynaud phenomenon

[Insufficient Evidence]

Dose: 120 mg PO tid

schizophrenia

[Possibly Effective]

Dose: 120-360 mg PO qd; Info: used w/ antipsychotic tx

sexual dysfxn

[Insufficient Evidence]

Dose: 150 mg PO bid

stroke

[Possibly Effective]

Dose: 17.5 g IV qd; Alt: 25 mg IV qd x14 days starting w/in 48h of sx onset

tardive dyskinesia

[Possibly Effective]

Dose: 80 mg PO tid

vascular dementia

[Possibly Effective]

Dose: 240 mg PO qd

vertigo

[Possibly Effective]

Dose: 120-160 mg/day PO divided qd-bid; Alt: 40 mg PO tid

vitiligo

[Insufficient Evidence]

Dose: 60 mg PO bid